Search

Your search keyword '"K, Bremer"' showing total 19 results
Start Over Author "K, Bremer" Journal oncology research and treatment
19 results on '"K, Bremer"'

1. Comparison of the Clinical Relevance of CEA, CA 15-3 and MCA in Breast Cancer

Author

G. Bremer, K. Bremer, S. Micus, and A. Eberhard

Subjects
Cancer Research, medicine.medical_specialty, Pathology, Receiver operating characteristic, business.industry, Clinical course, CA 15-3, Hematology, Serum concentration, medicine.disease, Gastroenterology, Breast cancer, Oncology, Internal medicine, medicine, Clinical significance, Enzyme immunoassays, business, Tumor marker
Abstract

Background: Tumor marker determinations are helpful parameters in the control and follow-up of the clinical course of neoplastic diseases. The serum concentrations of the three tumor markers CEA, CA 15-3 and MCA have been evaluated to comparatively investigate their clinical relevance in breast cancer patients. Patients and Methods: Simultaneous determinations of the serum concentrations of the three tumor markers CEA, CA 15-3 and MCA were performed in 419 sequential breast cancer patients. CEA and MCA were determined by means of enzyme immunoassays and CA 15-3 by a radio-immunoassay. Results: The serum concentrations of all three tumor markers correlate with tumor activity and tumor mass. The receiver operating characteristics (ROC) curves show that CA 15-3 has the greatest sensitivity and specificity. All three tumor markers did not reveal any dependence on age, but on the location of metastases; the median serum values decrease in the following sequence: osseous, visceral, and soft-tissue metastases. With a combination of tumor markers, the gain in sensitivity is associated with a loss of specificity, the combination of CEA + CA 15-3 appears to be the most favorable one. The combination of all three tumor markers does not show any advantage over the double combination CEA + CA 15-3. Conclusions: CA 15-3 has the highest sensitivity and specificity. As a combination of tumor markers CA 15-3 + CEA is recommended in breast cancer patients.

Published
1996

2. Randomisation und Patientenaufklärung

Author

B. Wiedenmann, A. Harstrick, G. Bremer, Michael Pfreundschuh, D. Sorger, Hans Scherübl, E. Heidemann, A. Resch-Holeczke, M. Korn, F. Riesen, A.W. Wassner, F. Walter, H.J. Weh, M. Rohrbacher, U. Haverkamp, S. Faiss, D. Depisch, E.-O. Riecken, Christoph Renner, Dirk Strumberg, B. Marian, Michael Hejna, T. Schenk, de Wit, Werner Scheithauer, M. Karall, H. Ofner, T. Zimmer, R. Pötter, Gabriela Kornek, Siegfried Seeber, C. Zornig, Joachim Baumgart, A. Eberhard, Heinz Ludwig, D.K. Hossfeld, H. Engler, Rainer Preiss, M. Schönfelder, Wilfried Eberhardt, Frank Hartmann, Hansjochen Wilke, M.E. Scheulen, U. Klaassen, R. Schmidt, G. Salem, S. Micus, Beat Thürlimann, and K. Bremer

Subjects
Cancer Research, Oncology, Hematology
Published
1996

3. Phase II Study of Subcutaneous Erythropoietin for Treatment of Myelodysplastic Syndromes (FAB Type I and II): A Trial of the Phase l/ll Study Group of the Association for Medical Oncology of the German Cancer Society

Author

G. Hartung, U. Essers, O. Quarder, M.E. Heim, S. Öhl, M. Baldus, K. Bremer, D. Fritze, Dieter Hoelzer, W. Queißer, A. Weigold, and Lutz Edler

Subjects
Ineffective erythropoiesis, Oncology, Cancer Research, medicine.medical_specialty, business.industry, Anemia, Myelodysplastic syndromes, Cancer, Phases of clinical research, Hematology, medicine.disease, medicine.disease_cause, Erythropoietin, hemic and lymphatic diseases, Internal medicine, Refractory anemia with ring sideroblasts, medicine, In patient, business, medicine.drug
Abstract

Background : Anemia in patients with myelodysplastic syndromes (MDS) is usually put down to ineffective erythropoiesis, although the contributory role of other mechanisms has not bee

Published
1995

4. Phase II Trial of Orally Administered Miltefosine in Advanced Colorectal Cancer

Author

R. Becher, H. Sindermann, A. Drozd, A. Füger, U.R. Kleeberg, D. Fritze, K. Rieche, K. Kloke, and K. Bremer

Subjects
Cancer Research, medicine.medical_specialty, Miltefosine, business.industry, Colorectal cancer, Nausea, Phases of clinical research, Cancer, Hematology, medicine.disease, Gastroenterology, Surgery, Oncology, Tolerability, Internal medicine, Toxicity, Vomiting, Medicine, medicine.symptom, business, medicine.drug
Abstract

Background: Treatment results in advanced colorectal cancer (CC) remain unsatis-factory and palliative, with 5-fluorouracil with or without calcium folinate being the only drug able to induce clinically acceptable response rates.Patients and Methods: A clinical phase II study is presented with an oral formulationof the phospholipid derivative miltefosine (MIL) in patients with advanced colorec-tal cancer. Patients were stratified according to pretreatment. Only non-pretreatedor pretreated patients who had received 5-fluorouracil with or without calcium folinate were accepted. MIL was given as capsule twice daily at a single dose of 50 mg for the 1st week with dose escalation to 150 mg (50 mg × 3) in the 2nd week and subsequently in case of good tolerability. Nine weeks were considered the minimal duration of treatment.Results: 54 patients were evaluable for toxicity and 44 were evaluable for response. A short-lived partial response was observed in one pretreated female patient with multiple lung lesions, a ‘no change’ status in 14 patients, including 8 nonpretreated patients (42%) and 6 pretreated patients (24%). Side effects were distinct, with loss of appetite, nausea and vomiting up to grade 4 WHO and weight loss of more than 5 kg in 3 months in a considerable number of patients. Furthermore, an increase of leukocyte and platelet counts was observed during the first 2 months of treatment. Conclusion: Oral MIL is considerably toxic and has only marginal therapeutic activity in patients with colorectal cancer.

Published
1993

5. Topically Applied Miltefosine (Hexadecylphosphocholine) in Patients with Skin-Metastasized Breast Cancer. A Phase II Study

Author

Lutz Edler, C. linger, Kurt Possinger, K. Bremer, H.J. Illiger, Wolfgang E. Berdel, M. Westerhausen, B. Jourdain-Madl, H.-E. Wander, K. Rieche, E. Heidemann, W. Queißer, Ulrich Gatzemeier, Reinhard Becher, Heinz H. Fiebig, U. Essers, U.R. Kleeberg, M.E. Heim, and R. Herrmann

Subjects
Oncology, Cancer Research, Miltefosine, medicine.medical_specialty, business.industry, Phases of clinical research, Hematology, Alkylphosphocholine, Pharmacology, medicine.disease, chemistry.chemical_compound, Breast cancer, chemistry, Internal medicine, medicine, In patient, business, medicine.drug
Abstract

Background: A clinical phase II study with a topical formulation of hexadecylphosphocholine (Miltefosine solution 6%) was performed in patients with skin-metas-tasized or locally re

Published
1993

6. Industrieforum – Industrial Forum

Author

E. Schulze, Michael Bamberg, R. Krahl, W. Helbig, M. Baur, Mathias Freund, E. Kaplan, E. Bauer, M. Goebel, S. Sandner, A. Drozd, Axel-R. Hanauske, Werner Hohenberger, Ch. Dittrich, M. Klee, K. Bremer, H. Poliwoda, O. Schlappack, Agnieszka Korfel, R. Becher, Lutz Edler, M. Westerhausen, M. Kawaguchi, U. Hofmann, S. Vijayakumar, Wolfgang E. Berdel, S. Burdach, J. Federbusch, Hans-Joachim Meyer, U. Hanauske, F.P. Gall, D. Neukam, S. Danhauser-Riedl, Johann Rastetter, H. Sakai, I. Körner, H. Kato, U. Essers, P. Hermanek jr., M. Zafferani, Hans-Rudolf Raab, Raimund Jakesz, R. Kolb, C. Konaka, P. Bachmann, T. Okunaka, W. de Riese, Clemens F. Hess, and Sabine Leiblein

Subjects
Cancer Research, Oncology, business.industry, Medicine, Hematology, business
Published
1992

7. Daily Oral Miltefosine (Hexadecyl-Phosphocholine) in Patients with Advanced Non-Small Cell Lung Cancer. A Phase II Study

Author

M. Westerhausen, Wolfgang E. Berdel, P. Bachmann, Agnieszka Korfel, R. Becher, M. Klee, U. Essers, K. Bremer, M. Zafferani, Lutz Edler, and A. Drozd

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Miltefosine, Pathology, business.industry, Phases of clinical research, Hematology, medicine.disease, respiratory tract diseases, chemistry.chemical_compound, chemistry, Internal medicine, Medicine, In patient, Non small cell, business, Lung cancer, Phosphocholine, medicine.drug
Abstract

A clinical phase II trial with an oral formulation of miltefosine (MIL) was performed in patients with non-small cell lung cancer (NSCLC). Eligibility criteria for this phase II study included histolo

Published
1992

8. Phase II Study of Vinorelbine by Oral Route (in a Hard Gelatine Capsule) for Metastatic Breast Cancer Patients

Author

F.M. Delgado, W. Queißer, A. Doss, R. Becher, K. Rieche, K. Bremer, Lutz Edler, and H.-E. Wander

Subjects
Oncology, Cancer Research, Oral treatment, medicine.medical_specialty, business.industry, Cytostatic agents, Phases of clinical research, Capsule, Hematology, Vinorelbine, medicine.disease, Metastatic breast cancer, Internal medicine, medicine, Oral route, Breast carcinoma, business, medicine.drug
Abstract

17 patients with advanced low-risk breast carcinoma not previously pretreated by cytostatic agents were treated by Vinorelbine (VIN), 5’-Nor-anhydro-vinblastine, a new semisynthetic compound of the vi

Published
1991

9. Oral Administration of Idarubicin as First Line Cytostatic Therapy in Patients with Metastasized Breast Cancer and Favourable Prognosis

Author

K. Possinger, H. Wagner, P. Worst, W. Queißer, K. Bremer, K. Rieche, M. Klee, M. Westerhausen, R. Donhuijsen-Ant, D. Fritze, L. Edler, G. Stiegelbauer, and K. Burk

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Anthracycline, business.industry, medicine.medical_treatment, Phases of clinical research, Bone metastasis, Hematology, medicine.disease, Metastatic breast cancer, Radiation therapy, Breast cancer, Internal medicine, medicine, Idarubicin, business, Survival rate, medicine.drug
Abstract

Idarubicin is a new anthracycline derivative with therapeutic efficacy in metastatic breast cancer. In a phase II trial we treated 23 patients with advanced breast carcinoma and favourable prognostic factors. Oral dose of idarubicin was 15 mg/m2 day 1-3 repeated every 3 weeks. All patients were pretreated with hormones. Idarubicin was administered as first line chemotherapy. 20 patients were evaluable for response: 3 patients achieved partial remission, 12 patients stable disease; tumour progression occurred in 5 patients. 3 patients were not evaluable for response because only 1 treatment cycle was administered. Main toxicites were leukopenia (median WHO-grade: 2,r:0-4), nausea and vomiting (median: 1,r:0-4) and alopezia (median: 1,r:0-3). 1 patient died in septic shock: Immediately after the administration of one idarubicine cycle, she was extensively irradiated because of bone metastasis. The fatal course of the disease in this patient does not depend only on the idarubicin therapy, but also on the extensive bone infiltration and on intensive radiation therapy. Idarubicin proved to be an effective drug in metastatic breast cancer with low systemic toxicity and the advantage of oral administration. The drug is an enrichment of therapeutic armament, especially in patients with soft tissue and bone metastasis.

Published
1991

10. Konsensus der CAO, AIO und ARO zur adjuvanten Therapie bei Kolon- und Rektumkarzinom vom 11.3.1994

Author

L. Edler, P.M. Schlag, G. Leppien, W.U. Knauf, H. Kriegbaum, E. Lengfelder, W.E. Berdel, T. Zwingers, H.-M. Reinold, W. Queißer, R. Herrmann, P.A. Palmer, H.H. Fiebig, F. Porzsolt, K. Pohlodek, E. Späth-Schwalbe, H.J. Senn, J.Th. Fischer, M. Hünerbein, J. Richner, H. Gallati, T. Hecht, R. Morant, P. Drings, B. Reufi, R. Becher, H. Sindermann, H. Arnold, C.A. Papadimitriou, G. Stohlmann, M. Aapro, K. Bremer, I. Funke, B. Rau, H. Schmid, B.M. Frey, E. Thiel, D. Oberberg, C. Manegold, A.-R. Hanauske, M. Lutz, A. Harstrick, M. Koenigsmann, E. Oelmann, H. Schrezenmeier, A. Gescher, W. Rauschning, S. Kerpel-Fronius, C. Bokemeyer, B. Steinke, M. Kaufmann, A. Münz, O. Prümmer, W.F. Riesen, H.-J. Schmoll, and M. Freund

Subjects
Cancer Research, Oncology, business.industry, Medicine, Hematology, business
Published
1994

11. llmofosine (BM 41.440) in Renal Cell Cancer – A Multicenter Phase II Study

Author

C. Manegold, H. Kriegbaum, Reinhard Becher, W. Queißer, K. Bremer, Lutz Edler, and R. Herrmann

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Gastrointestinal toxicity, Phases of clinical research, Hematology, chemistry.chemical_compound, Ether lipid, chemistry, Internal medicine, medicine, Cell cancer, Metastatic renal cell cancer, business
Abstract

Background : llmofosine is an ether lipid with antineoplastic activity in experimental systems. Since there is no established systemic treatment for metastatic renal cell cancer, a t

Published
1994

12. Pezcoller Foundation Trento Italia

Author

Ch. Kettelhack, K. Kloke, A. Drozd, M. Schröder, Th.W. Kraus, J.P. Droz, D.K. Hossfeld, Peter M. Schlag, M. Baldus, Maria P. Westarp, K. Mross, B. Wanjek, Hans Helmut Kornhuber, P.v. Brasch, Axel-R. Hanauske, W. Queißer, K. Rieche, A. Füger, U.R. Kleeberg, M.E. Westarp, Carsten Bokemeyer, K. Hamm, A. Ebert, S. Wilke, H.-J. Schmoll, B. Brockmann, K. Bremer, H. Sindermann, H. Brass, J. Bruynseels, G.P. Wildner, W. Bollag, D. Fritze, and Reinhard Becher

Subjects
Cancer Research, Oncology, Hematology
Published
1993

13. Interdisziplinäres Symposium der Arbeitsgemeinschaft Radiologische Onkologie (ARO) der Deutschen Krebsgesellschaft e.V., gemeinsam mit anderen Arbeitsgemeinschaften, der Sektion Radio-Onkologie der Deutschen Röntgengesellschaft e.V., der Bayerischen Röntgengesellschaft e.V. und dem Tumorzentrum Erlangen-Nürnberg

Author

Maria P. Westarp, Axel-R. Hanauske, D. Fritze, Th.W. Kraus, Hans Helmut Kornhuber, M.E. Westarp, W. Queißer, J.P. Droz, Ch. Kettelhack, A. Drozd, H. Brass, J. Bruynseels, K. Mross, Peter M. Schlag, M. Baldus, A. Füger, M. Schröder, K. Bremer, W. Bollag, A. Ebert, B. Wanjek, U.R. Kleeberg, D.K. Hossfeld, H. Sindermann, B. Brockmann, S. Wilke, H.-J. Schmoll, G.P. Wildner, Carsten Bokemeyer, K. Kloke, Reinhard Becher, K. Rieche, P.v. Brasch, and K. Hamm

Subjects
Cancer Research, Oncology, Hematology
Published
1993

14. Interferon α für die Therapie der HCL

Author

Bernd Dörken, U. Heinen, A. D. Ho, T. Zwingers, H. Fuhr, K. Straif, U. Papendick, D. Schuster, H. Gamm, J. Kraft, L. Nowicki, Andreas Neubauer, A. Heyll, U. Essers, H.A. Vaupel, M. Schrappe-Bächer, T.-H. Fischer, H. D. Bruhn, J. Hayungs, D. Asshoff, Arnold Ganser, R. M. Parwaresch, I. Schober, G. Pfannschmidt, K. Bremer, H. D. Schwöbel, A. Bartel, H. Pralle, Karl-Heinz Pflüger, R. Saß, K. Bross, S. Boedewadt-Radzun, N. Drees, A. Vonnegut, W. Schmidt, and H. Euler

Subjects
Gynecology, Cancer Research, medicine.medical_specialty, Oncology, Chemistry, medicine, Hematology
Abstract

Die Haarzelleukamie wurde mit α-2-Interferonen nach zwei aufeinander abgestimmten Therapieprotokollen behandelt. Die Wirksamkeit niedriger Tagesdosen konnte belegt werden und ebenso die geringe Rate an Nebenwirkungen. Die niedrigen Dosen verbesserten bei taglicher Applikation die hamatologischen und klinischen Parameter rasch, erzeugten aber eine erhohte Anfalligkeit fur todliche Infektio-nen bei Splenektomierten. Eine ebenso niedrig dosierte pulsatile Therapie wurde in das 2. Protokoll mit einem klar abgesetzten zeitlichen Verhalten fur die Splenektomierten eingesetzt, um die Bedeu-tung einer rhythmischen Applikation abschatzen zu lernen. Sie hat sich inzwischen und vorlaufig als wirksam und sicher erwiesen. Die weitere Entwicklung sicherer und nebenwirkungsarmer Therapien fur die HCL bleibt das Hauptziel der Studiengruppe. Der Stellenwert des bisher in der Rezidivbehandlung eingesetzten Desoxicoformicins [4, 7] wird noch zu erarbeiten sein.

Published
1988

15. Primäre Behandlung der Haarzelleukämie mit niedrigdosiertem humanem rekombinantem Interferon-Alpha-2c (Hr-IFn Alpha 2c) im Vergleich zur Therapie nach Splenektomie

Author

Arnold Ganser, J. Lohmeyer, A. D. Ho, K. Straif, M. Westerhausen, D. Schuster, T. Zwingers, J. Kraft, T.-H. Fischer, A. Goldmann, H. Gamm, J. Hayungs, D. Asshoff, Andreas Neubauer, R. M. Parwaresch, U. Papendick, K. Bross, K. Bremer, S. Boedewadt, Karl-Heinz Pflüger, P. Meier, L. Nowicki, R. Saß, H. Pralle, Norbert Schmitz, W. Schmidt, H. Euler, A. Heyll, U. Heinen, Bernd Dörken, and J. Hartlapp

Subjects
Gynecology, Cancer Research, medicine.medical_specialty, Oncology, business.industry, medicine, Alpha interferon, Hematology, business
Abstract

Innerhalb von weniger als 14 Monaten brachten 32 Kliniken 97 Patienten in eine multizentrische Studie zur Prufung einer niedrigdosierten Interferonbehandlung der Haarzelleukamie ein. Verwendet wurden

Published
1987

16. Sequentiell-alternierende Chemotherapie nicht-seminomatöser Hodentumoren mit Adriamycin/Cisplatin und Bleomycin/Vinblastin

Author

C. G. Schmidt, Jochen Schütte, Siegfried Seeber, Norbert Niederle, K. Bremer, and B. Schoetensack

Subjects
Oncology, Cisplatin, Cancer Research, Chemotherapy, medicine.medical_specialty, business.industry, medicine.medical_treatment, Histology, Hematology, Drug resistance, medicine.disease, Bleomycin, Vinblastine, chemistry.chemical_compound, Regimen, chemistry, Internal medicine, Medicine, business, Testicular cancer, medicine.drug
Abstract

The value of sequential alternating chemotherapy was analyzed retrospectively in 180 patients with disseminated, non-seminomatous testicular cancer. Response rates of adriamycin/cisplatin--(combination A) and bleomycin/vinblastine (combination B)--combination chemotherapy were evaluated separately with respect to tumor histology and tumor stages. Tumor response was achieved in 151 of 180 patients (84%) who were evaluable for adriamycin/cisplatin chemotherapy. Out of those, 91 of 117 patients (78%) pretreated with combination B and 60 of 63 patients (95%) without prior chemotherapy responded. Irrespective of pretreatment tumor response was observed in 131 of 157 patients (84%) evaluable for treatment with bleomycin/vinblastine. Resistance to combination A was 2.5 fold higher in embryonal carcinomas (class II of Dixon and Moore) than in choriocarcinomas (class V). Bleomycin/vinblastine-therapy failed more frequently in choriocarcinomas as compared to other histological categories (22% vs. 14%). This report also includes an analysis of treatment failures in different tumor stages. Both regimens were more frequently ineffective in tumor stages with a large tumor burden (stages II C and IV D). Patterns of cross-resistance were evaluated for both regimens. Response to adriamycin/cisplatin occurred in 18/26 patients (69%), when combination B had failed, and response to bleomycin/vinblastine was achieved in 14/24 patients (58%) when adriamycin/cisplatin had failed. In patients not responding to either regimen the treatment failure was already recognized after the first chemotherapeutic course in 93% of these cases.

Published
1983

17. Informationen für die Klinik

Author

G. Henze, M.R. Nowrousian, M. Schmidt, U. Papendick, W. Schmidt, B. Bonfert, W. Gassmann, J. Schwamborn, K.H. Pflüger, K. Mainzer, G. Middelhoff, N. Schmitz, R. Burkhardt, W.D. Gassel, R. Mertelsmann, I. Eschenbach, D. Hossfeld, A. Goldmann, E. Lengfelder, K.-H. Zurborn, J. Hayungs, K. Schuhmacher, Ch. Anders, P. Meyer, D.K. Hossfeld, H. Rühl, U. Bode, H. Jürgens, K. Havemann, F.-C. Wendt, R. Hehlmann, H.J. König, B. Emmerich, L. Demling, R. Kuse, P. Proksch, D. Asshoff, H. Euler, J. Hasford, H.A. Vaupel, K. Lennert, H. Pralle, E. Loetzke, T. Büchner, T. Kolb, F. Overkamp, T. Dettke, R. Jakesz, R.M. Parwaresch, H. Rainer, L. Nowicki, R. Häßler, R. Saß, T. Zwingers, G. von Speth, J. Fischer, P. Koch, W. Hiddemann, B. Dörken, L. Bergmann, D. Urbanitz, R. Zankovich, D. Dennig, W. Augener, C. Aul, A. Georgii, J. Lohmeyer, B. Anger, A. Von Paleske, J. Schüller, B. Heinze, B. Blöchl-Daum, F. Wendt, G. Ehninger, H.G. Eichler, K. Bross, H. Löffler, P. Meusers, F. Carbonell, A. Mohr, K. Bremer, U. Heinen, K. Straif, W. Meigel, M. Walter, H. Gamm, G. Maschmeyer, M. Westerhausen, H. Salzer, K.-P. Hellriegel, P. Rácz, H.W. Pees, E. Thiel, H.-J. Pielken, J. Ritter, M. Planker, A. Neiß, A. Ho, R. Donhuijsen-Ant, W. Queißer, A. Heyll, R. Pfab, H. Bartels, T. Fischer, H.H. Fülle, A.D. Ho, A. Neubauer, M. Dietrich, H. Seibt, J. Kraft, U. Essers, A. Heinecke, H. Köppler, G. Steger, P. Meier, G. Prindull, W. Siegert, W. Köpcke, J. Hartlapp, K. Pflüger, W.D. Ludwig, A. Ganser, D. Messerer, F. Porzsolt, E. Günther, A. Gottesleben, H. Kreutzmann, G. Schellong, W. Schneider, U. Creutzig, S. Boedewadt, D. Schuster, H.J. Kolb, P. Kern, F. Heiss, and H. Heimpel

Subjects
Cancer Research, Oncology, Hematology
Published
1987

18. Hinweise für Autoren / Sonderbände

Author

Norbert Niederle, J. Drescher, L. Boutis, H.D. Waller, S. Safarini, H.-J. Spaar, R. Bernsmeier, P. Thomas, H. Jürgens, E. Keiditsch, E. Ungeheuer, P. Ostendorf, Siegfried Seeber, B. Steinke, C.G. Schmidt, D. Gericke, H. Wacha, D. Mouratidou, P. Gutjahr, N. Bouchoris, Jochen Schütte, H. D. Bruhn, G. Landbeck, A.C. Voss, E. Holzgrebe, Chr. Lersch, K. Hatzigogos, P. Lück, A. Hofstetter, K. Bremer, J. Tavantzis, I. Thöne, K.H. Zurborn, S. Koukourikos, G Beron, U. Goebel, K. Winkler, J. Müller-Wickup, B. Schoetensack, K. Dimitriadis, and U. Blum

Subjects
Cancer Research, Oncology, Hematology
Published
1982

19. TNM-Klassifikation maligner Tumoren: Neue Auflage 1987

Author

H. Kreutzmann, D. Urbanitz, G. Maschmeyer, B. Blöchl-Daum, J. Lohmeyer, A. Heinecke, G. Ehninger, H.W. Pees, E. Thiel, D. Dennig, A. Georgii, E. Lengfelder, A. Neiß, U. Creutzig, H.G. Eichler, T. Fischer, L. Nowicki, K. Bremer, F. Carbonell, H.A. Vaupel, H. Seibt, A. Mohr, T. Büchner, K. Straif, H. Euler, D. Schuster, D. Hossfeld, H. Gamm, A.D. Ho, B. Anger, H. Pralle, S. Boedewadt, B. Heinze, J. Kraft, Ch. Anders, E. Loetzke, H.H. Fülle, W. Queißer, H. Köppler, R. Pfab, W.D. Gassel, T. Dettke, C. Aul, G. Schellong, W. Schneider, M. Planker, M. Dietrich, W. Meigel, P. Meier, G. Prindull, W. Schmidt, B. Bonfert, U. Essers, U. Bode, W. Siegert, H.J. Kolb, W. Hiddemann, R. Zankovich, F.-C. Wendt, H.-J. Pielken, K. Mainzer, P. Kern, B. Emmerich, R. Kuse, L. Demling, H. Rainer, P. Proksch, P. Koch, A. Heyll, J. Schüller, R.M. Parwaresch, K.H. Pflüger, G. von Speth, A. Neubauer, R. Burkhardt, G. Middelhoff, J. Schwamborn, N. Schmitz, K. Bross, J. Hayungs, F. Heiss, G. Steger, W. Augener, A. Von Paleske, M. Westerhausen, I. Eschenbach, H. Salzer, P. Meyer, H. Jürgens, P. Meusers, P. Rácz, D. Asshoff, J. Fischer, H. Heimpel, R. Mertelsmann, K.-H. Zurborn, T. Kolb, K. Schuhmacher, H. Löffler, H. Rühl, D.K. Hossfeld, R. Häßler, A. Ho, K. Havemann, U. Heinen, T. Zwingers, R. Hehlmann, J. Hasford, F. Wendt, K. Lennert, M. Walter, R. Saß, J. Ritter, W. Köpcke, A. Goldmann, H.J. König, F. Overkamp, B. Dörken, H. Bartels, K. Pflüger, W.D. Ludwig, K.-P. Hellriegel, J. Hartlapp, E. Günther, A. Gottesleben, R. Donhuijsen-Ant, R. Jakesz, L. Bergmann, A. Ganser, D. Messerer, F. Porzsolt, W. Gassmann, M. Schmidt, U. Papendick, G. Henze, and M.R. Nowrousian

Subjects
Cancer Research, Oncology, Hematology
Published
1987

Catalog

Books, media, physical & digital resources
See catalog results